We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) will announce quarterly earnings of $0.63 per share in its forthcoming report, representing an increase of 3.3% year over year. Revenues are projected to reach $4.29 billion, increasing 3% from the same quarter last year.
Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Teva Pharmaceutical Industries metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenue- COPAXONE- Total' at $101.85 million. The estimate indicates a change of -31.2% from the prior-year quarter.
Analysts expect 'Revenue- API sales to third parties' to come in at $156.49 million. The estimate indicates a change of +3.6% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Other- Total' will reach $259.03 million. The estimate indicates a change of +144.4% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenue- Europe' of $1.25 billion. The estimate points to a change of +3.3% from the year-ago quarter.
Analysts' assessment points toward 'Geographic Revenue- International Markets' reaching $602.40 million. The estimate points to a change of +1.6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Geographic Revenue- United States' will likely reach $2.19 billion. The estimate suggests a change of +3.6% year over year.
It is projected by analysts that the 'Geographic Revenue- United States- Anda' will reach $358.28 million. The estimate indicates a change of -4% from the prior-year quarter.
Analysts predict that the 'Geographic Revenue- Europe- COPAXONE' will reach $40.50 million. The estimate points to a change of -23.6% from the year-ago quarter.
Analysts forecast 'Geographic Revenue- Europe- Respiratory products' to reach $55.07 million. The estimate points to a change of -3.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Geographic Revenue- International Markets- Generic products' should arrive at $478.57 million. The estimate indicates a year-over-year change of -1.5%.
According to the collective judgment of analysts, 'Geographic Revenue- International Markets- COPAXONE' should come in at $10.83 million. The estimate indicates a change of -22.7% from the prior-year quarter.
The consensus estimate for 'Geographic Revenue- United States- AJOVY' stands at $50.80 million. The estimate points to a change of +21% from the year-ago quarter.
Shares of Teva Pharmaceutical Industries have demonstrated returns of -1.3% over the past month compared to the Zacks S&P 500 composite's +4.9% change. With a Zacks Rank #3 (Hold), TEVA is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
Analysts on Wall Street project that Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) will announce quarterly earnings of $0.63 per share in its forthcoming report, representing an increase of 3.3% year over year. Revenues are projected to reach $4.29 billion, increasing 3% from the same quarter last year.
Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Teva Pharmaceutical Industries metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenue- COPAXONE- Total' at $101.85 million. The estimate indicates a change of -31.2% from the prior-year quarter.
Analysts expect 'Revenue- API sales to third parties' to come in at $156.49 million. The estimate indicates a change of +3.6% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Other- Total' will reach $259.03 million. The estimate indicates a change of +144.4% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenue- Europe' of $1.25 billion. The estimate points to a change of +3.3% from the year-ago quarter.
Analysts' assessment points toward 'Geographic Revenue- International Markets' reaching $602.40 million. The estimate points to a change of +1.6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Geographic Revenue- United States' will likely reach $2.19 billion. The estimate suggests a change of +3.6% year over year.
It is projected by analysts that the 'Geographic Revenue- United States- Anda' will reach $358.28 million. The estimate indicates a change of -4% from the prior-year quarter.
Analysts predict that the 'Geographic Revenue- Europe- COPAXONE' will reach $40.50 million. The estimate points to a change of -23.6% from the year-ago quarter.
Analysts forecast 'Geographic Revenue- Europe- Respiratory products' to reach $55.07 million. The estimate points to a change of -3.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Geographic Revenue- International Markets- Generic products' should arrive at $478.57 million. The estimate indicates a year-over-year change of -1.5%.
According to the collective judgment of analysts, 'Geographic Revenue- International Markets- COPAXONE' should come in at $10.83 million. The estimate indicates a change of -22.7% from the prior-year quarter.
The consensus estimate for 'Geographic Revenue- United States- AJOVY' stands at $50.80 million. The estimate points to a change of +21% from the year-ago quarter.
View all Key Company Metrics for Teva Pharmaceutical Industries here>>>Shares of Teva Pharmaceutical Industries have demonstrated returns of -1.3% over the past month compared to the Zacks S&P 500 composite's +4.9% change. With a Zacks Rank #3 (Hold), TEVA is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .